H.C. Wainwright ups Trevi Therapeutics target after ‘best-case’ for CORAL

H.C. Wainwright raised the firm’s price target on Trevi Therapeutics (TRVI) to $7.50 from $6 and keeps a Buy rating on the shares after the company said the planned sample size re-estimation for the ongoing Phase 2b CORAL trial in idiopathic pulmonary fibrosis patients with chronic cough requires no change to the current sample size for the study, which the firm calls a “best-case outcome.” Topline CORAL data remain on track for the first half of 2025 and the firm calls the announcement “an unequivocal and material positive for investor risk-perception and optimism around Trevi heading into upcoming data catalysts.”